Physician profile
Blake Woods
NPI 1548665136
$6,150.06
in general payments reported to CMS, 2019-2025
34 companies · $870 in 2025
The $870 reported for 2025 was more than what 85% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,165 · 2022: $1,047 · 2023: $1,499 · 2024: $1,569 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,937.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $998.56 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $859.54 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $701.86 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $539.49 | 2021-2025 | Repatha, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $514.33 | 2021-2025 | Jardiance, Tradjenta |
| Abbvie INC. | $427.62 | 2021-2025 | |
| Pfizer INC. | $207.27 | 2021-2023 | |
| Glaxosmithkline, LLC. | $202.93 | 2021-2025 | Trelegy Ellipta |
| Dexcom, INC. | $194.44 | 2021-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $154.95 | 2021-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $152.13 | 2021-2024 | |
| Abbott Laboratories | $114.52 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $108.56 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $100.40 | 2021-2025 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $96.67 | 2022-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.26 | 2022-2024 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $86.76 | 2022-2024 | Gvoke Hypopen |
| Edwards Lifesciences Corporation | $69.91 | 2022-2024 | Sapien 3 Ultra Resilia |
| Axsome Therapeutics, INC. | $59.43 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $58.58 | 2024-2025 | Voquezna |
| Medtronic, INC. | $57.11 | 2021-2025 | Inceptiv |
| Mylan Specialty L.P. | $52.41 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $49.03 | 2023-2024 | Rexulti, Abilify Maintena, Jynarque |
| Merck Sharp & Dohme LLC | $42.99 | 2023 | Verquvo, Belsomra, Steglatro |
| Nestle Healthcare Nutrition INC. | $37.17 | 2023 | |
| Sumitomo Pharma America, INC. | $31.34 | 2023-2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $29.46 | 2024 | Quviviq |
| Boston Scientific Corporation | $22.38 | 2023 | Watchman Access System |
| Amarin Pharma, INC. | $18.55 | 2021 | |
| Lundbeck LLC | $16.58 | 2024 | Rexulti |
| Paratek Pharmaceuticals, INC. | $16.19 | 2023 | Nuzyra |
| Almatica Pharma LLC | $14.29 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.68 | 2025 | Zoryve |
| Adlon Therapeutics L.P. | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.